New Research Poster Presentation 2.35
A Phase III Clinical Endpoint Evaluation of HLD200 in Children With ADHD: Safety Results
Thursday, October 29, 2015 10:00 AM
Sharon Wigal, PhD, AVIDA Inc., Newport Beach, CA
Ann Catherine Childress, MD, Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV
Mary Ann McDonnell, PhD, South Shore Psychiatric Services, PC, Marshfield, MA
Scott H. Kollins, PhD, Duke University Medical Center, Durham, NC
Floyd R. Sallee, MD, PhD, University of Cincinnati, Edisto, SC
Norberto J. DeSousa, MA, Ironshore Pharmaceuticals & Development, Inc., Grand Cayman, Cayman Islands
